MyChesCo on MSN4h
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment
HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Healio1d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
PharmExec2d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Applied Clinical Trials Online1d
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...
GlobalData on MSN3d
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Investor's Business Daily on MSN3d
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
PMLive3d
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
Fierce Biotech4d
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Johnson & Johnson announces new icotrokinra data from Phase 3 program
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...